Plasmid News and Research

RSS

Stabilizing mutations in SARS-CoV-2 immunogens improve vaccine design

Researchers in the United States have developed stabilized immunogens presenting the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may improve the scalability of RBD-based coronavirus vaccines.

18 May 2021

Phase 2 trial shows INO-4800 SARS-CoV-2 DNA vaccine safe and tolerable in adults

Preliminary clinical trial results from an ongoing Phase 2/3 trial led by Laurent M. Humeau of Inovio Pharmaceuticals suggest the two-dose INO-4800 vaccine is safe for use in adults of varying ages. The results expand on phase 1 trial results that found the vaccine was safe and tolerable in 38 participants.

16 May 2021

An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo

A team of scientists from the Washington University School of Medicine and the University of Texas Medical Branch, USA, has recently evaluated the durability and robustness of an adenovirus-vectored, spike-based intranasal COVID-19 vaccine in mice.

11 May 2021

A new strain of common probiotic can potentially be more effective at protecting infant health

Researchers at the University of Helsinki have created a strain of the Lacticaseibacillus rhamnosus GG probiotic that is able to utilize both lactose and casein as well as reproduce in dairy products.

29 Apr 2021

New COVID-19 vaccine could provide protection against existing and future strains of coronaviruses

A COVID-19 vaccine that could provide protection against existing and future strains of the COVID-19 coronavirus, and other coronaviruses, and cost about $1 a dose has shown promising results in early animal testing.

19 Apr 2021

Candidate coronavirus vaccines show promising results in early animal testing

A candidate vaccine that could provide protection against the COVID-19 virus and other coronaviruses has shown promising results in early animal testing.

17 Apr 2021

New polypeptide could provide universal protection against coronaviruses

Researchers in the United States have developed an inhibitor of the spike protein found on the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that limits its formation in host human cells that would otherwise be the source of newly generated virions.

11 Apr 2021

South Africa SARS-CoV-2 variant B.1.351 easily escapes Sputnik vaccine

A new preprint research paper posted to the medRxiv* server reports on vaccine resistance data that pushes the end of the pandemic further away.

6 Apr 2021

Developing a COVID-19 vaccine using inactivated E. coli

A team of researchers inactivated whole-cell E.coli with a reduced genome and utilized this to express coronavirus-specific fusion peptides, demonstrating a potent anamnestic response.

19 Mar 2021

New study maps SARS-CoV-2 and host protein interactions in detail

A new study has developed a systemic map detailing the mechanistic interactions and disruptions between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its host cell.

18 Mar 2021

GMP-Ready Helper Plasmids for AAV Production

Manufactured in dedicated clean-rooms with mandated changeovers before new production cycles - AMSBIO introduces new pHelper-Kan plasmid DNA optimized for Adeno-Associated Virus (AAV) manufacturing.

18 Mar 2021

New Phase 1 study evaluates prime/boost HIV-1 vaccine formulated with combinations of adjuvants

A new Phase 1 vaccine study began today that will evaluate experimental prime/boost HIV-1 vaccine regimens formulated with combinations of different adjuvants, including one from the Army Liposome Formulation (ALF) family of adjuvants developed by scientists with the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research.

15 Mar 2021

Identification of neutralizing IFNL3 autoantibodies in severe COVID-19 cases

Scientists have recently developed a novel alternative molecular display technology called Molecular Indexing of Proteins by Self Assembly (MIPSA). Their research explains how this technology overcomes the critical disadvantages of PLATO and other full-length protein array technologies.

5 Mar 2021

Commonly used sweeteners may promote antibiotic resistance

Researchers in Australia have conducted a study showing that commonly used nonnutritive sweeteners can promote the spread of antibiotic-resistant genes in the intestine.

28 Feb 2021

Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site to Establish Global pDNA Development and Manufacturing Capabilities

Catalent and Delphi Genetics today announced that they have entered into a final and definitive agreement whereby Catalent will acquire 100% of the shares of Delphi Genetics.

26 Feb 2021

Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site to Establish Global pDNA Development and Manufacturing Capabilities

Catalent and Delphi Genetics today announced that they have entered into a final and definitive agreement whereby Catalent will acquire 100% of the shares of Delphi Genetics.

26 Feb 2021

An overview of spike protein antigen COVID-19 vaccine candidates

A new paper in the journal Reviews in Medical Virology provides a perspective on current vaccine development strategies and tools, which may allow the production of safe and effective vaccines.

22 Feb 2021

SARS-CoV-2 DNA vaccine tested in animal model

A team of experts has tested the immune responses elicited by mucosal homologous plasmid and a heterologous immunization strategy using a plasmid vaccine and a Modified Vaccinia Ankara (MVA) expressing SARS-CoV-2 spike (S) and nucleocapsid (N) antigens.

21 Feb 2021

Advancements in DNA vaccines against COVID-19

The rapid spread of the pathogen and the increasing number of cases highlight the need for an effective and safe vaccine. As vaccination efforts roll out in many countries, new types of vaccines, like deoxyribonucleic acid (DNA) vaccines, are under research..

17 Feb 2021

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

Researchers shows a fully human immunoglobulin (IgG) that potently inhibits SARS-CoV-2 infection.

10 Feb 2021

Plasmid News and Research

Stabilizing mutations in SARS-CoV-2 immunogens improve vaccine design

Phase 2 trial shows INO-4800 SARS-CoV-2 DNA vaccine safe and tolerable in adults

An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo

A new strain of common probiotic can potentially be more effective at protecting infant health

New COVID-19 vaccine could provide protection against existing and future strains of coronaviruses

Candidate coronavirus vaccines show promising results in early animal testing

New polypeptide could provide universal protection against coronaviruses

South Africa SARS-CoV-2 variant B.1.351 easily escapes Sputnik vaccine

Developing a COVID-19 vaccine using inactivated E. coli

New study maps SARS-CoV-2 and host protein interactions in detail

GMP-Ready Helper Plasmids for AAV Production

New Phase 1 study evaluates prime/boost HIV-1 vaccine formulated with combinations of adjuvants

Identification of neutralizing IFNL3 autoantibodies in severe COVID-19 cases

Commonly used sweeteners may promote antibiotic resistance

Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site to Establish Global pDNA Development and Manufacturing Capabilities

Catalent to Acquire Delphi Genetics and Launch US Plasmid Manufacturing Site to Establish Global pDNA Development and Manufacturing Capabilities

An overview of spike protein antigen COVID-19 vaccine candidates

SARS-CoV-2 DNA vaccine tested in animal model

Advancements in DNA vaccines against COVID-19

Polyclonal SARS-CoV-2 antibody shows potent neutralizing activity in vitro

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest Life Science News